Frequency Electronics Inc. Announces Contract Awards Valued at Approximately $45 million MITCHEL FIELD, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM), a leading provider of precision timing and frequency control products for space and terrestrial applications, is pleased to announce the award of two contracts for satellite programs. One contract is in the domain of FEI’s traditional space satellite programs, and one is part of the new proliferated satellite paradigm. The contracts are valued at approximately $45 million on a co...
Frequency Electronics, Inc. Announces Third Quarter and Fiscal Year 2026 Financial Results MITCHEL FIELD, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) is pleased to announce its financial results for the third quarter and fiscal year 2026. Revenue for the three and nine months ended January 31, 2026, was approximately $16.9 million and $47.8 million, respectively, compared to $18.9 million and $49.8 million, respectively, reported for the same period of fiscal year 2025. Operating income for the three and nine months ended Ja...
Frequency Electronics Announces Third Quarter Fiscal 2026 Financial Results Conference Call: Wednesday, March 11, 2026, at 4:30 PM ET MITCHEL FIELD, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. (NASDAQ: FEIM), will hold a conference call to discuss results for the third quarter of its fiscal year 2026, ended January 31, 2026, on Wednesday, March 11, 2026, at 4:30 PM Eastern Time. This call is being webcast by Issuer Direct Corporation and can be accessed in the Investor Relations section of Frequency’s web site at . Investors and analysts may also access the call ...
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will deliver a poster presentation on the company’s lead asset, CUE-401, at the World Immune Regulation Meeting (WIRM) being held March 11-14, 2026 in Davos, Switzerland. The presentation w...
Methode Electronics, Inc. Reports Fiscal 2026 Third Quarter Financial Results Progress on transformation amid mixed market conditions Net sales of $233.7 million, down 2.6% year-over-yearNet loss of $15.9 million or 6.8% of net sales; adjusted EBITDA margin of 3.1%Narrowed FY26 sales guidance, lowered adjusted EBITDA guidance to $58 to $62 millionFinalized agreement for the sale of Harwood Heights, IL facilitySubsequent to quarter-end, closed on the sale of dataMate business, purchase price of $16 million SOUTHFIELD, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Methode Electronics, ...
Methode Electronics Announces Sale of dataMate Business SOUTHFIELD, Mich., March 05, 2026 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI) today announced the sale of its dataMate copper transceiver business to Bel Fuse Inc.® (NASDAQ: BELFA, BELFB), a leading global manufacturer of products that power, protect, and connect electronic circuits. The divestiture will enable Methode to sharpen the focus on key growth strategies, particularly in the area of power solutions, with a focus on data center business and power delivery and distribution products, anticipating the increasingly...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing ...
A director at Arista Networks Inc sold/sold after exercising options 8,000 shares at 128.672USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directo...
A director at Greif Inc sold 11,607 shares at 72.212USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of International Flavors & Fragrances, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 25 February 2026 in which we reassessed the appropriateness of the...
Methode Electronics Announces Third Quarter Fiscal 2026 Results Conference Call SOUTHFIELD, Mich., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, announced it will conduct a conference call and webcast on Friday, March 6, 2026, at 11:00 a.m. EST to review its third quarter fiscal 2026 results. President and Chief Executive Officer, Jon DeGaynor, and Chief Financial Officer, Laura Kowalchik will lead the call. The presentation will be webcas...
OPKO Health to Participate in the Jefferies Biotech on the Beach Summit MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biopharmaceutic...
FY4Q25 (December) Key Measures & FY26 GuidanceTotal revenue increased 22% y/y to $72.4 million which was above the Street’s estimate of $69.5 million as the company is seeing broad-based demand for frontier model training, agentic AI, and physical AI.Adj. EBITDA of $15.7 million came in above t
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This n...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.